title: Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.
abstract: OBJECTIVE
  We aimed to assess a functional polymorphism in FCGR2A H131R, for association with the treatment response to Fc-containing inhibitors of tumor necrosis factor (TNF).
  
  
  METHODS
  A total of 429 biologic-naive patients with rheumatoid arthritis collected in two sets (299 and 130) were treated during standard care with infliximab (INX), etanercept, or adalimumab. Response to the treatment was evaluated at 3, 6, and 12 months of follow-up as the change in the Disease Activity Score (DAS) 28 from baseline and as the response by the European League Against Rheumatism (EULAR) criteria. These variables were analyzed for association with linear and logistic regression models that included sex, inhibitors of TNF, and baseline DAS28 as covariates.
  
  
  RESULTS
  Significant association was found between the FCGR2A H131R polymorphism and the response to treatment with INX, but not with the other two TNF inhibitors. The 131R allele was associated with a lower change in DAS28 (P=0.04-0.008 at different times) in the first set of patients and confirmed in the second group of patients (P=0.026 at 3 months of follow-up). Association was also found in the comparison between nonresponders and responders to INX by the EULAR criteria.
  
  
  CONCLUSIONS
  We found an association of the FCGR2A 131R allele with poor response to INX. This finding could be of utility to understand the mechanisms behind treatment failure and contribute to biomarker panels for INX response prediction.
authors.affiliation: aResearch Laboratory 10 and Rheumatology Unit, Health Research Institute, University Clinic Hospital of Santiago bDepartment of Medicine, University of Santiago de Compostela, Santiago de Compostela cRheumatology Unit, University Hospital of Bellvitge dRheumatology Unit, University Hospital Clinic eRheumatology Unit, Hospital Santa Creu e San Pau, Barcelona fRheumatology Unit, University Hospital Virgen Macarena, Sevilla gUGC of Rheumatology, University Regional Hospital of Málaga, Biomedical Research Institute of Málaga, University of Málaga, Málaga hRheumatology Unit, University Hospital Virgen de las Nieves, Granada iRheumatology Unit, Hospital 12 of October, Madrid, Spain jDepartament of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: Ariana
authors.initials: A
authors.lastname: Montes
authors.forename: Eva
authors.initials: E
authors.lastname: Perez-Pampin
authors.forename: Javier
authors.initials: J
authors.lastname: Narváez
authors.forename: Juan D
authors.initials: JD
authors.lastname: Cañete
authors.forename: Federico
authors.initials: F
authors.lastname: Navarro-Sarabia
authors.forename: Virginia
authors.initials: V
authors.lastname: Moreira
authors.forename: Antonio
authors.initials: A
authors.lastname: Fernández-Nebro
authors.forename: María
authors.initials: M
authors.lastname: Del Carmen Ordóñez
authors.forename: Arturo R
authors.initials: AR
authors.lastname: de la Serna
authors.forename: Berta
authors.initials: B
authors.lastname: Magallares
authors.forename: Yiannis
authors.initials: Y
authors.lastname: Vasilopoulos
authors.forename: Theologia
authors.initials: T
authors.lastname: Sarafidou
authors.forename: Rafael
authors.initials: R
authors.lastname: Caliz
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Ferrer
authors.forename: Beatriz
authors.initials: B
authors.lastname: Joven
authors.forename: Patricia
authors.initials: P
authors.lastname: Carreira
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Gómez-Reino
authors.forename: Antonio
authors.initials: A
authors.lastname: Gonzalez
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C445323:FCGR2A protein, human; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab